Corynebacterium parvum versus BCG adjuvant immunotherapy in human malignant melanoma
- PMID: 6821809
- DOI: 10.1002/1097-0142(19830101)51:1<57::aid-cncr2820510114>3.0.co;2-v
Corynebacterium parvum versus BCG adjuvant immunotherapy in human malignant melanoma
Abstract
One-hundred and sixteen patients with Stage I and Stage II malignant melanoma were randomized to treatment with either Bacillus Calmette-Guerin (BCG) (Tice) or subcutaneous Corynebacterium parvum (Burroughs-Wellcome). Life table analysis failed to reveal a difference between these two forms of treatment in 68 Stage I patients. The relapse rate was significantly reduced in Stage II patients treated with C. parvum.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Medical